Adherence to black box warnings for prescription medications in outpatients

Archives of Internal Medicine

Volumn 166, Issue 3, 2006, Pages

  Lasser, Karen E ^a,f   Seger, Diane L ^b   Yu, D Tony ^c   Karson, Andrew S ^d   Fiskio, Julie M ^b   Seger, Andrew C ^b,c,e   Shah, Nidhi R ^c   Gandhi, Tejal K ^c   Rothschild, Jeffrey M ^c   Bates, David W ^b,c  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b PARTNERS HEALTHCARE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARBAMAZEPINE; CORTICOSTEROID; DEXTROPROPOXYPHENE; LITHIUM CARBONATE; LITHIUM CITRATE; METFORMIN; TRIAMTERENE; VALPROIC ACID;

ADULT; AGED; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DOCTOR PATIENT RELATION; DRUG INFORMATION; DRUG PREFERENCE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; MEDICATION ERROR; MULTIVARIATE ANALYSIS; OFF LABEL DRUG USE; OUTPATIENT; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; AMBULATORY CARE; BOSTON; DRUG LABELING; FEMALE; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SEX FACTORS;

EID: 32644436054     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.166.3.338     Document Type: Article

References (27)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
2. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
3. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556-1564.
4. Hutchinson TA, Flegel KM, Kramer MS, Leduc DG, Kong HH. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis. 1986;39:533-542.
5. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45:945-948.
6. Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med. 2000;15:149-154.
7. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652-1658.
8. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.
9. Marcus SC, Olfson M, Pincus HA, Zarin DA, Kupfer DJ. Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder. Am J Psychiatry. 1999;156:1014-1018.
10. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286:831-833.
11. Stelfox HT, Ahmed SB, Fiskio J, Bates DW. Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice. Clin Pharmacol Ther. 2004;75:110-122.
12. Horlen C, Malone R, Bryant B, et al. Research letter: frequency of inappropriate metformin prescriptions. JAMA. 2002;287:2504-2505.
13. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA. 2000;284:3036-3039.
14. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf. 2005;28:67-80.
15. Merlo J, Liedholm H, Lindblad U, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ. 2001;323:427-428.
16. Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co Inc; 2002.
17. Proposed rules. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/ 122200a.htm. Accessed August 12, 2005.
18. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001;161:53-58.
19. Generali J. Drugs with black box warnings. Available at: http://www.formularyproductions .com/master/showpage.php?dir= blackbox&whichpage=238. Accessed August 24, 2005.
20. Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J. 1998;53:403-411.
21. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140:795-801.
22. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
23. Walker AM, Bortnichak EA, Lanza L, Yood RA. The infrequency of liver function testing in patients using nonsteroidal anti-inflammatory drugs. Arch Fam Med. 1995;4:24-29.
24. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 2003;290:81-85.
25. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994;151(suppl):1-36.
26. Audet AM, Doty MM, Peugh J, Shamasdin J, Zapert K, Schoenbaum S. Information technologies: when will they make it into physicians' black bags? MedGenMed. 2004;6:2.
27. Smith PC, Araya-Guerra R, Bublitz C, et al. Missing clinical information during primary care visits. JAMA. 2005;293:565-571.